8-1-13 9:15 AM EDT | Email Article
http://media.marketwire.com/attachments/201304/142926_142915_decisiondiagnostics_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1039085&ProfileId=051205&sourceType=1

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip™, the Green Glucose Test Strip, specifically designed to work with Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today the filing of counterclaims by its subsidiary Pharma Tech Solutions, Inc. for false and misleading advertising against two of Johnson & Johnson, Inc. ("J&J") wholly owned subsidiaries, Lifescan, Inc., and Lifescan Scotland, LTD (collectively "Lifescan"). The company and its Pharma Tech Solutions, Inc. ("Pharma Tech") subsidiary have been in patent litigation with the Lifescan subsidiaries since September 2011.

J&J's wholly owned subsidiary Lifescan manufactures and sells blood glucose monitoring systems, which include meters and test strips, under the OneTouch® Ultra® brand name. Lifescan is the market share leader in the at-home glucose testing market. The company's Pharma Tech subsidiary competes directly with J&J Lifescan in the market for at-home glucose test strips by offering the Shasta GenStrip™, a unique diagnostic testing strip, that has received FDA clearance for at-home use with certain OneTouch® Ultra® meters. The GenStrip™ is a lower-cost alternative to the OneTouch® Ultra® test strip that works with specific OneTouch® Ultra® meters and costs significantly less than the J&J Lifescan product.

In 2012, immediately following FDA clearance of the GenStrip™, Lifescan moved the Federal District Court to enjoin sales and distribution of the competitive GenStrip™. While a Federal District Court for the Northern District of California granted Lifescan a preliminary injunction, the Federal Circuit Court quickly stayed the injunction and the matter currently awaits a near term ruling.

Today, Pharma Tech seeks leave from the District Court, in the court room of a judge new to the aforementioned September 2011 case, to amend its counterclaim against J&J Lifescan, based on anti-competitive actions by Lifescan, so that a claim for false advertising can be added.

J&J Lifescan promotes its OneTouch® Ultra® system as having "Double Sure technology," which supposedly "automatically checks... each blood a sample twice to assure that [the user is] receiving the most accurate results." By this representation, J&J Lifescan falsely conveys to consumers that its OneTouch® Ultra® system provides more accurate results than the competition, including the GenStrip™. By virtue of proposed amendment to its counterclaim, Pharma Tech intends to prove that this representation is misleading and untrue and that OneTouch® Ultra® system actually likely provides less accurate results than much of its competition.

DECN's Pharma Tech subsidiary is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies. The FDA cleared Shasta GenStrip™ product was first introduced to the market in late 2012 as a lower cost (50%) alternative for user/owners of the J&J LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose meters.

Forward-Looking Statements:
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

For further information about Shasta Genstrip, please visit the company's Web Sites: http://www.decisiondiagnostics.com or http://www.shastagenstrip.com. The company's Genstrip videos can be viewed at http://www.pharmatechdirect.com. A new video is currently in production.

GenStrip™ test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan®, Inc. a Johnson & Johnson® Company, manufacturers and distributors of the OneTouch® Ultra® Family of Meters and OneTouch® Ultra® test strips.


Keith Berman
Secretary and CFO
2660 Townsgate Road
Suite 300
Westlake Village, CA 91361
Ph: 805-446-2973
Fax: 805-446-1983

Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division  |  Next: Decision Diagnostics' Board Votes to Uplist to OTC QX